- Hikma projects a full-year core operating profit between $730 million and $770 million.
- The estimated core operating profit is approximately $735.3 million.
- Group revenue is expected to grow by 4% to 6% within the year.
- Most core operating profit growth is anticipated in the second half of the year.
- The company is keeping an eye on changing tariff conditions but has not factored tariffs into the full-year forecast.
- Analyst recommendations for Hikma include 9 ‘buy’ ratings, 3 ‘hold’ ratings, and no ‘sell’ ratings.
A look at Hikma Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Hikma Pharmaceuticals shows a promising long-term outlook. With strong scores in Growth and Momentum, the company seems well-positioned for expansion and positive market performance. Its focus on developing, manufacturing, and marketing a variety of pharmaceutical products indicates potential for sustained growth in the industry.
Although the company’s scores in Value, Dividend, and Resilience are not as high as Growth and Momentum, they still fall within a solid range, suggesting overall stability and decent investment potential. Hikma Pharmaceuticals‘ multinational presence across regions like the United States, the Middle East, North Africa, and Europe offers geographic diversification that may contribute to its resilience in varying market conditions.
Summary of the company: Hikma Pharmaceuticals PLC is a multinational pharmaceutical group engaged in the development, production, and promotion of a broad range of generic and in-licensed pharmaceutical products. Its operations span across key regions including the United States, the Middle East, North Africa, and Europe, showcasing a diversified market presence.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
